Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.

The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate ...

Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast ...

Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

Jeffrey Wong, MD, discusses the evolving field of combination therapy with radiopharmaceuticals in prostate cancer. In an interview with Targeted Oncology TM, Jeffrey Wong, MD, radiation oncologist ...